Skip to content
DraconiticResearch
Search Sources API
186,631 studies31 sourcesUpdated 47 min ago
Peer-reviewedCC BYZhongguo fei ai za zhi = Chinese journal of lung cancer

[Variant Allele Frequency Stratification and EGFR Co-mutation Characteristics in AKT1 E17K-mutant Non-small Cell Lung Cancer].

  1. 1Department of Pathology, Beijing Chest Hospital, Capital Medical University/ Beijing Tuberculosis and Thoracic Tumor Research Institute, Beijing 101149, China.

Abstract

Background

AKT serine/threonine kinase 1 (AKT1) E17K, the most common activating mutation of AKT1, is an established druggable driver in breast cancer; however, it is exceedingly rare in non-small cell lung cancer (NSCLC), with its clinical significance remaining unclear. Variant allele frequency (VAF) may partially reflect the clonal proportion of a mutation, offering clues to the clonal characteristics of such rare mutations. This study investigated the relationship between AKT1 E17K VAF and co-mutation with classic driver genes such as epidermal growth factor receptor (EGFR) in NSCLC, aiming to explore the potential role of this mutation in tumor clonal evolution.Methods

Next-generation sequencing (NGS) data of lung cancer patients at Beijing Chest Hospital, Capital Medical University from June 2019 to April 2026 were retrospectively analyzed. After deduplication of 13,003 tests, 11,368 unique patients (including small cell lung cancer) were identified, among whom 35 harbored AKT1 E17K mutations (overall detection rate 0.31%), all being NSCLC; 5 external consultation cases were excluded, leaving 30 cases for analysis. Continuous VAF analysis was designated as the primary analysis, with an exploratory cutoff of 10%.Results

Of the 30 patients, 20 (66.7%) were adenocarcinoma. Median follow-up was 12 months (range: 1-55 months). The EGFR co-mutation rate was lower in the high-VAF group (≥10%, n=17) than in the low-VAF group (<10%, n=13; 11.8% vs 46.2%), reaching nominal significance before correction [P=0.049, odds ratio (OR)=0.156] but not after Bonferroni adjustment (adjusted P=0.246). The median VAF was lower in the EGFR co-mutated group than in the EGFR wild-type group (1.37% vs 13.73%, P=0.071). Continuous analysis showed a negative trend between VAF and EGFR co-mutation (ρ=-0.340, P=0.066). After adjusting for histological type using Firth-corrected Logistic regression, the direction of the association remained unchanged but was no longer nominally significant (OR=0.21, 95%CI: 0.03-1.33, P=0.097).Conclusions

AKT1 E17K VAF showed a negative trend with EGFR co-mutation; however, the association did not remain significant after correction for multiple comparisons or adjustment for histological type, and may be partly influenced by histological composition. These findings should be regarded as hypothesis-generating and require validation in larger multi-center cohorts.

Related

  1. Elevated Allele Frequency of a Common Germline PDCD1 Variant Associated with Leukocytosis and Thrombocytopenia in Acute Myeloid Leukemia Treated with HDCT/ASCT
    Katja Seipel, Ranja Leuenberger, Henning Nilius +5
    CancersPeer-reviewedCC BY 4.0OncologyCrossref
  2. Prognostic implications of TET2 variant allele frequency in chronic myelomonocytic leukemia: a multicenter study.
    Yu-Hung Wang, Dorothée Selimoglu-Buet, Carmelo Gurnari +16
    Blood neoplasiaPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  3. Combined Point Mutation in a Single Allele of the TP53 Gene Potentiates the Oncogenic and Transcriptional Properties of TP53 in Lung Cancer.
    Sicheng Bian, Huiqin Bian, Hiroaki Koyama +7
    International journal of biological sciencesPeer-reviewedCC BYFull textOncologyEurope PMC
  4. FFT-GA-BC: a fused federated transformer genetic algorithm framework with blockchain-secured, differentially private, homomorphically encrypted aggregation for mutation, phenotype, and binary-allele analysis.
    Muhammad Umar Nasir, Urva Rehmat, Abdul Khader Jilani Saudagar +3
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. RAS Mutations as Prognostic Biomarkers in Digestive Cancers: From Binary Classification to Variant-Specific and Context-Dependent Risk Stratification
    Lucien Grados, Rami Rhaiem, Koceila Amroun +5
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
BibTeX
@article{zhao2026variant,
  title = {{[Variant Allele Frequency Stratification and EGFR Co-mutation Characteristics in AKT1 E17K-mutant Non-small Cell Lung Cancer].}},
  author = {Dan Zhao and Deyang Xie and Nana Zhang and Lili Zhang and Kun Li and Nanying Che},
  journal = {Zhongguo fei ai za zhi = Chinese journal of lung cancer},
  year = {2026},
  month = aug,
  doi = {10.3779/j.issn.1009-3419.2026.106.24},
  url = {https://europepmc.org/article/MED/42896970},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - [Variant Allele Frequency Stratification and EGFR Co-mutation Characteristics in AKT1 E17K-mutant Non-small Cell Lung Cancer].
AU  - Dan Zhao
AU  - Deyang Xie
AU  - Nana Zhang
AU  - Lili Zhang
AU  - Kun Li
AU  - Nanying Che
PY  - 2026
DA  - 2026/08/01
JO  - Zhongguo fei ai za zhi = Chinese journal of lung cancer
DO  - 10.3779/j.issn.1009-3419.2026.106.24
UR  - https://europepmc.org/article/MED/42896970
AB  - Background  AKT serine/threonine kinase 1 (AKT1) E17K, the most common activating mutation of AKT1, is an established druggable driver in breast cancer; however, it is exceedingly rare in non-small cell lung cancer (NSCLC), with its clinical significance remaining unclear. Variant allele frequency (VAF) may partially reflect the clonal proportion of a mutation, offering clues to the clonal characteristics of such rare mutations. This study investigated the relationship between AKT1 E17K VAF and co-mutation with classic driver genes such as epidermal growth factor receptor (EGFR) in NSCLC, aiming to explore the potential role of this mutation in tumor clonal evolution.Methods  Next-generation sequencing (NGS) data of lung cancer patients at Beijing Chest Hospital, Capital Medical University from June 2019 to April 2026 were retrospectively analyzed. After deduplication of 13,003 tests, 11,368 unique patients (including small cell lung cancer) were identified, among whom 35 harbored AKT1 E17K mutations (overall detection rate 0.31%), all being NSCLC; 5 external consultation cases were excluded, leaving 30 cases for analysis. Continuous VAF analysis was designated as the primary analysis, with an exploratory cutoff of 10%.Results  Of the 30 patients, 20 (66.7%) were adenocarcinoma. Median follow-up was 12 months (range: 1-55 months). The EGFR co-mutation rate was lower in the high-VAF group (≥10%, n=17) than in the low-VAF group (<10%, n=13; 11.8% vs 46.2%), reaching nominal significance before correction [P=0.049, odds ratio (OR)=0.156] but not after Bonferroni adjustment (adjusted P=0.246). The median VAF was lower in the EGFR co-mutated group than in the EGFR wild-type group (1.37% vs 13.73%, P=0.071). Continuous analysis showed a negative trend between VAF and EGFR co-mutation (ρ=-0.340, P=0.066). After adjusting for histological type using Firth-corrected Logistic regression, the direction of the association remained unchanged but was no longer nominally significant (OR=0.21, 95%CI: 0.03-1.33, P=0.097).Conclusions  AKT1 E17K VAF showed a negative trend with EGFR co-mutation; however, the association did not remain significant after correction for multiple comparisons or adjustment for histological type, and may be partly influenced by histological composition. These findings should be regarded as hypothesis-generating and require validation in larger multi-center cohorts.
SN  - 1009-3419
SN  - 1999-6187
ER  -